Hereditary Hemorrhagic Telangiectasia (HHT) Center
This grant supports clinical partnerships, better diagnosis, and a patient data registry to improve care and outcomes for people with Hereditary Hemorrhagic Telangiectasia (HHT).
Funder: Health Resources and Services Administration
Due Dates (Anticipated): June 2026 (full application deadline, projected)
Funding Amounts: Up to $2,900,000 total; one award anticipated; no cost sharing required
Summary: Supports a center to reduce illness and death from Hereditary Hemorrhagic Telangiectasia (HHT) by expanding care access, supporting clinician diagnosis, and developing a patient data registry.
Key Information: This is a forecasted opportunity; all dates are projected and subject to change.
Description
This program aims to reduce morbidity and mortality associated with Hereditary Hemorrhagic Telangiectasia (HHT), a rare genetic disorder. The initiative will partner with a clinical center to:
- Expand access and coordination of care for HHT patients,
- Develop innovative strategies to help clinicians identify and diagnose HHT cases, and
- Create a de-identified, aggregate patient data registry to improve understanding of HHT and its treatment outcomes.
The award will be made as a cooperative agreement, supporting activities that enhance the detection, management, and data-driven understanding of HHT.
